This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Gregory Verdine | |
|---|---|
| Name | Gregory Verdine |
| Birth date | 1956 |
| Nationality | American |
| Fields | Chemical biology, biochemistry, chemical synthesis |
| Workplaces | Harvard University, Dana–Farber Cancer Institute, Novo Nordisk Foundation Center for Protein Research |
| Alma mater | University of Wisconsin–Madison, Columbia University |
Gregory Verdine is an American chemist and chemical biologist notable for pioneering approaches to target intracellular protein–protein interactions and for founding multiple biotechnology companies. His work spans academic research at Harvard University and translational efforts with firms in the biotechnology and pharmaceutical industry, influencing drug discovery paradigms and intellectual property strategies.
Verdine was born in the United States and completed undergraduate studies at University of Wisconsin–Madison before earning a Ph.D. at Columbia University. During his doctoral and postdoctoral training he interacted with researchers in chemical biology, organic chemistry, and molecular biology, aligning with laboratories associated with figures linked to Harvard Medical School and the Massachusetts Institute of Technology. His training connected him with communities around institutions such as Dana–Farber Cancer Institute and centers that collaborate with National Institutes of Health research programs.
Verdine served as a faculty member at Harvard University in departments interfacing with Harvard Medical School and contributed to programs affiliated with Dana–Farber Cancer Institute and the Broad Institute. He held laboratory leadership roles, mentored graduate students and postdoctoral fellows who later joined organizations including Pfizer, Novartis, Merck & Co., Amgen, Genentech, and Biogen. His academic collaborations included investigators from Stanford University, MIT, Yale University, University of California, San Francisco, and international centers such as ETH Zurich and Max Planck Society institutes.
Verdine's research established methods in synthetic peptide chemistry and cell-permeable stabilized helices to modulate intracellular interactions relevant to targets studied by teams at GlaxoSmithKline, AstraZeneca, Johnson & Johnson, and academic groups at Columbia University and University of California, Berkeley. He introduced strategies that intersect with disciplines and efforts at Cold Spring Harbor Laboratory, Salk Institute, Scripps Research, and the Rockefeller University. His work on stapled peptides and constrained peptide scaffolds influenced projects at Genentech and collaborations with structural biology groups at European Molecular Biology Laboratory and cryo-EM centers linked to Howard Hughes Medical Institute. Verdine's publications and patents have shaped discovery efforts against targets relevant to oncology and infectious diseases investigated by teams at Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Center, Cleveland Clinic, and Johns Hopkins University.
Verdine co-founded and advised multiple companies translating academic concepts into therapeutics, engaging with investors and partners from Flagship Pioneering, Sequoia Capital, Khosla Ventures, Atlas Venture, and Third Rock Ventures. Startups he helped found and lead connected to drug-development pipelines and alliances with Bristol-Myers Squibb, Eli Lilly and Company, Takeda Pharmaceutical Company, and contract research organizations working with Catalent and Charles River Laboratories. His entrepreneurial activities intersected with incubators and accelerators associated with Cambridge Innovation Center and university technology transfer offices at Harvard University and Massachusetts Institute of Technology. Companies he founded engaged in licensing and mergers with entities similar to Astellas Pharma and Sanofi and collaborated with translational initiatives at Wellcome Trust-linked projects.
Verdine has received recognition from scientific societies and institutions that also honor researchers from American Chemical Society, National Academy of Sciences, American Association for the Advancement of Science, and philanthropic organizations like Howard Hughes Medical Institute and Gordon and Betty Moore Foundation. His work has been cited in award contexts alongside laureates from Nobel Prize-associated research programs and honored in lists and lectures at venues including Cold Spring Harbor Laboratory meetings, symposia at Royal Society, and conferences organized by American Society for Biochemistry and Molecular Biology.
Category:American chemists Category:Biotechnologists